Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-08-14

FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approves a supplemental application for LAMICTAL (lamotrigine) submitted by GlaxoSmithKline LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LAMICTAL (LAMOTRIGINE)

Snippet

SUPPL AP for LAMICTAL (LAMOTRIGINE)